FILTER
FILTERED INTERVIEW RESULTS
Nicolas Konialidis & Craig Mynhardt
CEO & GM FOR AFRICA, IMPALA TERMINALS
Impala Terminals is expanding its services in sub Saharan Africa in tandem with the development of the mining industry and with the continents infrastructure developments.
Geert Klok
GENERAL MANAGER, GK ANCUABE GRAPHITE MINE, S.A.
GK Ancuabe graphite mine has expanded its capacity, offering an alternative to graphite from China and demonstrating that successful mining can be achieved in Mozambique.
Gareth Clifton
GENERAL MANAGER MOZAMBIQUE, KENMARE RESOURCES
Kenmare discusses its operations in Mozambique and the challenges currently facing the country.
Errol Smart
MD AND CEO, ORION MINERALS
Orion Minerals will be South Africa’s next copper and zinc producer with the Prieska project being a copper-predominant project. Full development is scheduled to begin in early 2020.
Roger Dixon
CORPORATE CONSULTANT, SRK CONSULTING
SRK’s team in South Africa sees increased opportunity in environmental and social governance issues.
Olivier Duterme
REGIONAL DIRECTOR, BANQUE COMMERCIALE DU CONGO (BCDC)
BCDC has existed as a leading domestic bank for 110 years in the Democratic Republic of Congo.
Paulo Reis
MANAGING PARTNER, EY MOZAMBIQUE
EY Mozambique sees opportunity to capitalize on the extractive industries to benefit the country’s development of other sectors.
Adry Nzonzimbu
DIRECTOR, MINEQUIP
Minequip prepares to transform its operations in the DRC with the opening of a new warehouse and repair facility this year.
Deon Heyns
CEO, CONGO EQUIPMENT
Congo Equipment is the official CAT dealer for the mining region of DRC.
Louison Kiyombo
PARTNER, KPMG
KPMG draws on global experience and local expertise to help clients navigate the DRC’s complicated legislative framework.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
